A Phase I Trial of Combination Gemcitabine and Nab-Sirolimus in Advanced Leiomyosarcomas or Advanced Soft-Tissue Sarcomas With TSC2 or TSC1 Loss-of-function Mutations or Deletions
Active, not recruiting · Phase 1 · NCT06308419
Conditions: Leiomyosarcoma, Soft-tissue Sarcomas
At a glance
- Research payments reported, 2025
- $295,356
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 18
About the trial
- Sponsor
- M.D. Anderson Cancer Center (with Aadi Bioscience)
- Tested
- Gemcitabine (drug), Nab-Sirolimus (drug)
- Dates
- Started 2024-08-14; completion 2031-02-01
- Results posted
- Not yet
To find a recommended dose of gemcitabine and nab-sirolimus that can be given in combination to participants with advanced leiomyosarcomas or soft-tissue sarcomas.
From ClinicalTrials.gov, last updated 2026-10-27. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Aadi Bioscience, Inc. reported $295,356 in research payments for this study in 2025 (3 payments).
Products named: Fyarro
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Ut MD Anderson Cancer Center $295,356
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.